B&K Corp Begins Phase IIIa Trial of Core Burn-Treatment Candidate Pro-101-1 with First Patient Enrollment

Bulletin Express05-12

B&K Corporation Limited (B&K Corp) has enrolled the first patient in its Phase IIIa clinical trial of Pro-101-1, a recombinant human platelet-derived growth factor BB (rhPDGF-BB) gel under development for the treatment of deep second-degree burns.

The randomized, double-blind, placebo-controlled study is designed to assess the efficacy and safety of Pro-101-1 in a large patient cohort and to generate key parameters for the subsequent Phase IIIb trial. Management positions the program as a major research-and-development milestone in the company’s burns-treatment pipeline.

Pro-101-1 is identified by B&K Corp as one of its core assets. The initiation of a Phase IIIa study marks a critical step toward potential commercialization, subject to successful completion of later-stage trials and regulatory approvals.

Pursuant to Rule 18A.05 of the Hong Kong Listing Rules, B&K Corp cautions that it cannot guarantee the ultimate success or market launch of Pro-101-1. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1197970022?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-12 21:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197970022","market":"hk","top_or_hot":-1,"title":"B&K Corp Begins Phase IIIa Trial of Core Burn-Treatment Candidate Pro-101-1 with First Patient Enrollment","media":"Bulletin Express","content":"<p>B&K Corporation Limited (B&K Corp) has enrolled the first patient in its Phase IIIa clinical trial of Pro-101-1, a recombinant human platelet-derived growth factor BB (rhPDGF-BB) gel under development for the treatment of deep second-degree burns.</p>\n<p>The randomized, double-blind, placebo-controlled study is designed to assess the efficacy and safety of Pro-101-1 in a large patient cohort and to generate key parameters for the subsequent Phase IIIb trial. Management positions the program as a major research-and-development milestone in the company’s burns-treatment pipeline.</p>\n<p>Pro-101-1 is identified by B&K Corp as one of its core assets. The initiation of a Phase IIIa study marks a critical step toward potential commercialization, subject to successful completion of later-stage trials and regulatory approvals.</p>\n<p>Pursuant to Rule 18A.05 of the Hong Kong Listing Rules, B&K Corp cautions that it cannot guarantee the ultimate success or market launch of Pro-101-1. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>B&K Corp Begins Phase IIIa Trial of Core Burn-Treatment Candidate Pro-101-1 with First Patient Enrollment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nB&K Corp Begins Phase IIIa Trial of Core Burn-Treatment Candidate Pro-101-1 with First Patient Enrollment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-12 21:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>B&K Corporation Limited (B&K Corp) has enrolled the first patient in its Phase IIIa clinical trial of Pro-101-1, a recombinant human platelet-derived growth factor BB (rhPDGF-BB) gel under development for the treatment of deep second-degree burns.</p>\n<p>The randomized, double-blind, placebo-controlled study is designed to assess the efficacy and safety of Pro-101-1 in a large patient cohort and to generate key parameters for the subsequent Phase IIIb trial. Management positions the program as a major research-and-development milestone in the company’s burns-treatment pipeline.</p>\n<p>Pro-101-1 is identified by B&K Corp as one of its core assets. The initiation of a Phase IIIa study marks a critical step toward potential commercialization, subject to successful completion of later-stage trials and regulatory approvals.</p>\n<p>Pursuant to Rule 18A.05 of the Hong Kong Listing Rules, B&K Corp cautions that it cannot guarantee the ultimate success or market launch of Pro-101-1. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02396","symbol_name":"华芢生物-B","start_time":0,"source_url":"","article_id":"1197970022","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197970022","pubTimestamp":1778592180,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"B&K Corporation Limited (B&K Corp) has enrolled the first patient in its Phase IIIa clinical trial of Pro-101-1, a recombinant human platelet-derived growth factor BB (rhPDGF-BB) gel under...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02396":"华芢生物-B"},"translate_title":"B&K Corp开始核心烧伤治疗候选药物Pro-101-1的IIIa期试验，并招募了第一名患者","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02396":1},"content_text":"B&K Corporation Limited (B&K Corp) has enrolled the first patient in its Phase IIIa clinical trial of Pro-101-1, a recombinant human platelet-derived growth factor BB (rhPDGF-BB) gel under development for the treatment of deep second-degree burns.\nThe randomized, double-blind, placebo-controlled study is designed to assess the efficacy and safety of Pro-101-1 in a large patient cohort and to generate key parameters for the subsequent Phase IIIb trial. Management positions the program as a major research-and-development milestone in the company’s burns-treatment pipeline.\nPro-101-1 is identified by B&K Corp as one of its core assets. The initiation of a Phase IIIa study marks a critical step toward potential commercialization, subject to successful completion of later-stage trials and regulatory approvals.\nPursuant to Rule 18A.05 of the Hong Kong Listing Rules, B&K Corp cautions that it cannot guarantee the ultimate success or market launch of Pro-101-1. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1197970022","isCrawlerRequest":true}